Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors

Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant’s FDA approval in ovarian cancer and likely approval in Cushing’s syndrome could drive CORT revenues above $3 billion annually by decade’s end. 2026 revenue guidance of $950M–$1.05B reflects >30% YoY growth, with minimal impact expected from generic competition due to pipeline innovation. Despite a forward P/S of ~10x, CORT’s $10B+ market cap is justified by multi-billion dollar peak revenue potential and expanding clinical pipeline.

It has been almost exactly six years since I last covered Corcept Therapeutics Incorporated ( CORT ) in a note for Seeking Alpha, assigning the stock a Buy rating - a good call, as